HWG Holdings LP Has $952,000 Holdings in Boston Scientific Co. (NYSE:BSX)

HWG Holdings LP increased its stake in shares of Boston Scientific Co. (NYSE:BSX - Free Report) by 65.2% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 10,655 shares of the medical equipment provider's stock after acquiring an additional 4,207 shares during the period. HWG Holdings LP's holdings in Boston Scientific were worth $952,000 at the end of the most recent reporting period.

A number of other institutional investors also recently made changes to their positions in BSX. Janney Montgomery Scott LLC raised its position in shares of Boston Scientific by 4.3% in the 4th quarter. Janney Montgomery Scott LLC now owns 207,162 shares of the medical equipment provider's stock valued at $18,504,000 after purchasing an additional 8,522 shares in the last quarter. Brighton Jones LLC raised its position in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after purchasing an additional 226 shares in the last quarter. CX Institutional raised its position in shares of Boston Scientific by 16.5% in the 4th quarter. CX Institutional now owns 10,245 shares of the medical equipment provider's stock valued at $915,000 after purchasing an additional 1,451 shares in the last quarter. Fifth Third Bancorp increased its holdings in shares of Boston Scientific by 4.4% in the 4th quarter. Fifth Third Bancorp now owns 228,556 shares of the medical equipment provider's stock valued at $20,415,000 after acquiring an additional 9,610 shares during the last quarter. Finally, Grimes & Company Inc. increased its holdings in shares of Boston Scientific by 61.9% in the 4th quarter. Grimes & Company Inc. now owns 12,943 shares of the medical equipment provider's stock valued at $1,156,000 after acquiring an additional 4,951 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Boston Scientific news, SVP Vance R. Brown sold 4,826 shares of the company's stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total value of $458,904.34. Following the completion of the transaction, the senior vice president now directly owns 36,193 shares in the company, valued at approximately $3,441,592.37. This represents a 11.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP John Bradley Sorenson sold 4,572 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the completion of the transaction, the executive vice president now owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 191,155 shares of company stock worth $19,556,047 in the last three months. 0.50% of the stock is owned by corporate insiders.

Boston Scientific Price Performance

Shares of Boston Scientific stock traded up $0.58 on Friday, reaching $105.08. 10,524,691 shares of the stock were exchanged, compared to its average volume of 6,427,290. The firm's 50 day moving average is $100.29 and its 200-day moving average is $97.88. Boston Scientific Co. has a one year low of $71.88 and a one year high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a market cap of $155.46 billion, a PE ratio of 84.06, a P/E/G ratio of 2.79 and a beta of 0.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. The company had revenue of $4.66 billion during the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the firm posted $0.56 EPS. The firm's quarterly revenue was up 20.9% on a year-over-year basis. As a group, analysts anticipate that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on BSX. Needham & Company LLC reiterated a "buy" rating and issued a $115.00 price target on shares of Boston Scientific in a report on Wednesday. Evercore ISI upped their price objective on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Citigroup reissued a "buy" rating and issued a $125.00 price target (up previously from $119.00) on shares of Boston Scientific in a research report on Thursday, May 22nd. Morgan Stanley lifted their target price on shares of Boston Scientific from $120.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, May 16th. Finally, Raymond James lifted their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a "strong-buy" rating in a research note on Thursday, February 6th. Twenty-one analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus price target of $116.00.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.